21 CFR Part 11 is the FDA regulation that establishes thecriteria under which electronic records and electronic signatures areconsidered trustworthy, reliable, and generally equivalent to paper records andhandwritten signatures.
Part 11 applies to electronic records that are created,modified, maintained, archived, retrieved, or transmitted under FDA recordrequirements. It also applies to electronic records submitted to the FDA underapplicable legal requirements. It does not automatically apply to everyelectronic file or every system used by an FDA-regulated organization. Itsapplicability depends on the records involved and the relevant predicate rules.
Part 11 controls may include system validation, protectionof records, restricted system access, secure and computer-generated audittrails, operational and authority checks, record retention, and controls forelectronic signatures. Procedural controls are equally important and commonlyinclude approved SOPs, training, accountability, and defined responsibilities.
For QA and IT-QA teams, Part 11 applicability should beassessed as part of the system’s intended use and regulatory scope. If aplatform manages regulated electronic records or signatures, the assessmentshould address the applicable validation, access-control, audit-trail,record-retention, and electronic-signature requirements.
Cloud and SaaS platforms do not remove these obligations.The regulated company retains accountability for compliance but may rely onappropriately assessed supplier controls, services, and evidence.Responsibilities between the regulated company and the service provider shouldbe clearly defined.
Frequently Asked Questions
Does 21 CFR Part 11 apply to cloud and SaaS systems?
It can. Part 11 applicability is determined by theelectronic records and signatures managed by the system, not by where thesoftware or data is hosted. A cloud provider may operate infrastructure,security controls, backups, or other technical services. However, the regulatedcompany remains accountable for evaluating whether the system is fit for itsintended use and whether the applicable Part 11 controls are adequatelyimplemented.
What is the difference between 21 CFR Part 11 and EU GMP Annex 11?
Part 11 is a binding FDA regulation focused on electronicrecords and electronic signatures. EU GMP Annex 11 provides guidance forcomputerized systems used in GMP-regulated activities and addresses thecomputerized-system life cycle more broadly. Organizations operating in bothmarkets can use a harmonized governance framework, but it should be mapped tothe specific requirements applicable in each jurisdiction.
Are electronic signatures legally equivalent to handwritten signaturesunder Part 11?
They can be. When electronic signatures and their associatedrecords meet Part 11 requirements, the FDA considers them equivalent tohandwritten signatures, initials, and other general signings unlessspecifically excepted by regulation. Organizations using electronic signaturesunder Part 11 must also submit the required certification to the FDA.
What Part 11 weaknesses are commonly identified during assessments?
Common areas of concern include inadequate validationevidence, shared or poorly controlled user accounts, ineffective audit-trailcontrols, incomplete access management, and procedures that do not reflectactual system use. The relevance of each control depends on the system’sintended use, the records it manages, and the applicable predicate rules.